01
Overview
Prevep is a biotechnology company focused on the development of long-acting therapeutics for the prevention and treatment of infectious diseases, with a primary emphasis on HIV. The company's lead program is a novel, long-acting small molecule formulation designed to simplify pre-exposure prophylaxis (PrEP) regimens and improve patient adherence. By leveraging advanced drug delivery technologies, Prevep aims to provide sustained-release options that reduce the frequency of dosing compared to current daily oral therapies. The company is currently advancing its lead candidate through early-stage clinical trials to evaluate safety, tolerability, and pharmacokinetic profiles.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Prevep.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prevep.